Qoreishi S, Tabari M, Gaman M, Kazeminejad A
Avicenna J Med Biotechnol. 2024; 16(3):146-155.
PMID: 39132629
PMC: 11316511.
DOI: 10.18502/ajmb.v16i3.15740.
Ishii T, Matsue Y, Matsunaga Y, Iekushi K, Homma Y, Morita Y
Heart Vessels. 2023; 39(1):25-34.
PMID: 37695543
DOI: 10.1007/s00380-023-02304-2.
Lteif C, Ataya A, Duarte J
J Am Heart Assoc. 2021; 10(11):e020633.
PMID: 34032129
PMC: 8483544.
DOI: 10.1161/JAHA.120.020633.
Rueda P, Merlin J, Chimenti S, Feletou M, Paysant J, White P
Front Pharmacol. 2021; 12:628060.
PMID: 33776771
PMC: 7991592.
DOI: 10.3389/fphar.2021.628060.
Pitoulis F, Watson S, Perbellini F, Terracciano C
Cardiovasc Res. 2019; 116(7):1275-1287.
PMID: 31868875
PMC: 7243278.
DOI: 10.1093/cvr/cvz341.
Development of hypotension in patients newly diagnosed with heart failure in UK general practice: retrospective cohort and nested case-control analyses.
Martin-Perez M, Michel A, Ma M, Rodriguez L
BMJ Open. 2019; 9(7):e028750.
PMID: 31300503
PMC: 6629451.
DOI: 10.1136/bmjopen-2018-028750.
Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies.
Ge Z, Li A, McNamara J, Dos Remedios C, Lal S
Heart Fail Rev. 2019; 24(5):743-758.
PMID: 31209771
DOI: 10.1007/s10741-019-09806-0.
Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization.
Bhagat A, Greene S, Vaduganathan M, Fonarow G, Butler J
JACC Heart Fail. 2018; 7(1):1-12.
PMID: 30414818
PMC: 8053043.
DOI: 10.1016/j.jchf.2018.06.011.
Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs.
Kithcart A, MacRae C
JACC Basic Transl Sci. 2018; 2(1):1-12.
PMID: 30167552
PMC: 6113531.
DOI: 10.1016/j.jacbts.2017.01.004.
Mihai Gheorghiade, MD-Life and Concepts.
Pang P, Collins S, Butler J, Chioncel O
Am J Ther. 2018; 25(4):e453-e455.
PMID: 29916855
PMC: 6037549.
DOI: 10.1097/MJT.0000000000000797.
CRRL269: a novel designer and renal-enhancing pGC-A peptide activator.
Chen Y, Harty G, Huntley B, Iyer S, Heublein D, Harders G
Am J Physiol Regul Integr Comp Physiol. 2017; 314(3):R407-R414.
PMID: 29187381
PMC: 6425618.
DOI: 10.1152/ajpregu.00286.2017.
Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial.
Vaduganathan M, Cheema B, Cleveland E, Sankar K, Subacius H, Fonarow G
Eur J Heart Fail. 2017; 20(4):677-686.
PMID: 29143416
PMC: 6676477.
DOI: 10.1002/ejhf.973.
Expert consensus document: Mitochondrial function as a therapeutic target in heart failure.
Brown D, Perry J, Allen M, Sabbah H, Stauffer B, Shaikh S
Nat Rev Cardiol. 2016; 14(4):238-250.
PMID: 28004807
PMC: 5350035.
DOI: 10.1038/nrcardio.2016.203.
Angiotensin-Neprilysin Inhibition as a Paradigm for All?.
Vaduganathan M, Desai A
Curr Cardiol Rep. 2016; 18(11):115.
PMID: 27747488
DOI: 10.1007/s11886-016-0784-z.
Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure.
Greene S, Sabbah H, Butler J, Voors A, Albrecht-Kupper B, Dungen H
Heart Fail Rev. 2015; 21(1):95-102.
PMID: 26701329
DOI: 10.1007/s10741-015-9522-7.
